Pioneering Gene Writing™—a new genome engineering technology that writes therapeutic messages into the genome to treat diseases at their source

Developing a machine learning-powered platform can rapidly invent new drugs across a wide range of protein modalities and previously undiscoverable protein therapeutics

RNAi platform derived from cityRNAs

Focused on cellular rejuvenation programming to restore cell health and resilience, with the goal of reversing disease to transform medicine

Creating a next-generation enzymatic DNA synthesis platform

Developing a small molecule therapeutics platform for addressing strongly validated yet historically undruggable targets in oncology, rare diseases, neurodegeneration and autoimmunity

Developing CD8 T cell immune modulators for the treatment of autoimmune diseases

Developing microscale robots to deliver biologics or small molecule therapies locally to targeted disease

Computational biotechnology company creating a novel class of medicines to precisely target disease biology

Creating endless RNA (eRNA™) —a new class of programmable medicines capable of expressing therapeutic proteins inside the body.

Developing first-in-class gene therapies, Anellovector™ therapies, using a novel viral vector platform based on its groundbreaking work on the human commensal virome

Developing drugs that reprogram cellular microenvironments to send signals intended to have curative effects.